Portugal’s Master Plan project concentrates on children’s handball, with increasing player numbers and education the path to ...

We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...

U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – ...

HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two ...

Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 ...

The HIMUDA board approved new townships in Baddi, Pachhad, and near Kangra Airport. It also sanctioned the Jathia Devi project near Shimla, a special housing quota for awardees, and key policy reforms ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease ...

Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

In order to move forward, it is expected that existing data from the Phase 2b/3 Anavex 2-73 AD-004 program be submitted to the FDA. In December, as expected, the CHMP adopted a negative opinion on the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...